Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 27Solid Tumors 15Advanced Solid Tumors 12Solid Tumor 10Advanced Solid Tumor 5Mesothelioma 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumours 3Triple Negative Breast Neoplasms 2Solid Tumor, Adult 2Neoplasms 2Mesothelioma, Malignant 2Carcinoma, Renal Cell 2Advanced Solid Tumour 2Advanced Solid Tumor Cancer 2Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor - Protocol Specific 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Triple Negative Metastatic Breast Cancer 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Recurrent Malignant Solid Neoplasm 1Prostatic Neoplasms 1Peritoneal Neoplasms 1

Interventions

vorolanib 3neratinib 3toripalimab 1dacomitinib 1Vinorelbine 1TAK-243 1Premedication 1Paclitaxel 1Injections 1Immune Checkpoint Inhibitors 1Clinical Trials, Phase II as Topic 1Capecitabine 11-(4-(4-(3-oxa-8-azabicyclo(3.2.1)octan-8-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignant Solid Tumors × Paclitaxel × Other solid neoplasm × Clear all
NCT00768469 2018-11-19

Study Evaluating Safety And Tolerability, Solid Tumor

Puma Biotechnology, Inc.

Phase 1 Completed
10 enrolled 11 charts
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡